wire - news in brief



Results 1 - 50 of 1666.
1 2 3 4 5 ... 34 Next »

Environment - Pharmacology - 17.11.2021
World Toilet Day 2021: The toilet revolution is here
World Toilet Day 2021: The toilet revolution is here
In professional circles, there is talk of a toilet revolution. What exactly is going on here? It is not only about the toilet itself, but also highly about the treatment of excreta.

Health - Pharmacology - 09.11.2021
A first for Switzerland: proton therapy to treat lung cancer
A first for Switzerland: proton therapy to treat lung cancer
Today a 60-year-old patient suffering from lung cancer received proton beam therapy, a medical procedure where positively charged particles are precisely targeted at the tumour.

Health - Pharmacology - 25.10.2021
Roche launches comprehensive genomic profiling kit to expand access to personalised cancer research
The AVENIO Tumor Tissue Comprehensive Genomic Profiling (CGP) Kit is the first jointly-developed product that brings together the expertise and reach of Roche with Foundation Medicine's pioneering leadership in genomic science.

Pharmacology - 20.10.2021
TB-PRACTECAL: Clinical Trial Yields Promising Results for Drug-Resistant Tuberculosis Treatment
TB-PRACTECAL, a clinical trial led by Médecins Sans Frontières with partners including Swiss TPH, has found that a new all-oral treatment regimen for rifampicin-resistant tuberculosis (RR-TB) is safer and more effective than the current accepted standard of care.

Pharmacology - Health - 14.10.2021
Roche’s Gazyvaro shorter 90-minute infusion time approved in Europe for people with previously treated or untreated follicular lymphoma
Short duration infusion of Gazyvaro (obinutuzumab) is administered with a target infusion time of 90 minutes, compared to the current standard infusion time of approximately three to four hours Resul

Health - Pharmacology - 08.10.2021
Wyss Center announces new collaboration to improve brain tumor treatment
Wyss Center announces new collaboration to improve brain tumor treatment
Translational project will create the first detailed 3D maps of human glioblastomas with an integrated 'tissue time machine' to predict response to therapies Geneva, Switzerland - The Wyss Center ann

Pharmacology - Health - 07.10.2021
Novartis to present broad range of portfolio data at ECTRIMS, reinforcing long-standing commitment to people living with multiple sclerosis
Novartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta (ofatumumab) and Mayzent (siponimod) Novartis will be commencing Phase III pivotal trials investigating remibrutinib in RMS.

Pharmacology - Health - 07.10.2021
Erster Malaria-Impfstoff von der WHO für Kinder empfohlen
Yesterday, the World Health Organization (WHO) recommended the widespread use of the malaria vaccine RTS,S/AS01, debuting a tool that could save the lives of tens of thousands of children in sub-Saharan Africa each year.

Pharmacology - Health - 01.10.2021

Pharmacology - Health - 30.09.2021
Novartis data show rapid and effective disease activity control with remibrutinib (LOU064) in patients with chronic spontaneous urticaria
Results from a Phase IIb study show all remibrutinib doses provided significant improvements in UAS7 change from baseline at week 4 and week 12 compared to placebo, and a favorable safety profile acr

Pharmacology - Health - 29.09.2021
Novartis data show achieving complete control of chronic spontaneous urticaria (CSU) improves overall quality of life, as reported by patients
Data analysis shows that preventing the symptoms of CSU (achieving complete control) improves overall health-related quality of life (HRQoL); including sleep and work productivity, among other measur

Pharmacology - Health - 29.09.2021
New data reinforce efficacy and convenience of Novartis Cosentyx (secukinumab) 300 mg autoinjector in adults with psoriasis
New findings show Cosentyx (secukinumab) 300 mg single dose autoinjector (the UnoReady pen) resulted in superior efficacy vs placebo 1 Patient satisfaction with 300 mg autoinjector was high - reachin

Pharmacology - Health - 29.09.2021
Novartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malaria
Novartis and Medicines for Malaria Venture (MMV) report positive Phase 2b study results for novel non-artemisinin combination to treat uncomplicated malaria In the Phase 2b study conducted in childre

Health - Pharmacology - 22.09.2021
Roche launches three respiratory test panels on cobas 6800/8800 Systems in CE markets to help identify multiple pathogens with overlapping symptoms in patients
Acute respiratory infections are one of the leading causes of death and disability globally, presenting substantial health challenges especially for infants, the elderly and the immunocompromised.

Pharmacology - Health - 19.09.2021
Novartis presents new Kisqali data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced bre

Pharmacology - Health - 17.09.2021
Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)
PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies in blood vessels, the lymphatic system and other tissues At 24 week

Health - Pharmacology - 17.09.2021
Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021
New quality of life data for 177 Lu-PSMA-617 plus standard of care shows delay in worsening of health-related quality of life (HRQoL) and pain in heavily pre-treated patients with PSMA-positive metas

Health - Pharmacology - 13.09.2021

Pharmacology - Health - 30.08.2021
Novartis Leqvio * (inclisiran) analyses show effective and sustained LDL-C reduction in two sub-populations of patients with ASCVD
Separate post hoc analyses of pooled Phase III ORION-9, -10 and -11 data show twice-yearly** Leqvio (inclisiran) consistently reduced low-density lipoprotein cholesterol (LDL-C) in patients with athe

Health - Pharmacology - 25.08.2021
Tailoring Treatment of Patients with the Lung Disease COPD
Patients with COPD are treated with drugs to improve the breathing ability in combination with inhaled corticosteroids to reduce the risk of acute worsening of the lung conditions. But the balance between reduced exacerbations and increased adverse effects of the drugs depends on the dose and on patient characteristics.

Pharmacology - Health - 24.08.2021
Novartis provides update on BELINDA study investigating Kymriah as second-line treatment in aggressive B-cell non-Hodgkin lymphoma
Phase III BELINDA study did not meet primary endpoint of event-free survival for patients with aggressive B-cell non-Hodgkin lymphoma who had primary refractory disease or who relapsed within 12 mont

Pharmacology - Health - 18.08.2021
Rheon Medical is revolutionizing the surgical treatment of glaucoma
EPFL spin-off Rheon Medical has developed the world's first adjustable glaucoma drainage system, which has already been used successfully in over 250 patients in Europe.
1 2 3 4 5 ... 34 Next »